Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.38 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.38 |
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 4/20 | 0.35 |
| ▸ | DUSP5 | Q16690 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 5/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP9 | P55211 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553415 | 1.00 | CA12 (0.38) | CA12CA1CA2CA9PKLR | |
| Indigotindisulfonate SCHEMBL40486 | 0.84 | CA12 (0.50) | CA12CA1CA2CA9PKLR | |
| Indigotindisulfonate SCHEMBL29352151 | 0.84 | CA12 (0.50) | CA12CA1CA2CA9PKLR | |
| Indigotindisulfonate SCHEMBL118376 | 0.84 | CA12 (0.50) | CA12CA1CA2CA9PKLR | |
| Potassium Ion SCHEMBL2867164 | 0.84 | CA12 (0.40) | CA12CA1CA2CA9PKLR | |
| Indigotindisulfonate SCHEMBL20775438 | 0.83 | CA12 (0.49) | CA12CA1CA2CA9PKLR | |
| SCHEMBL5355942 | 0.82 | CA12 (0.38) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL5355940 | 0.82 | CA12 (0.38) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL2300219 | 0.77 | CA12 (0.44) | CA12CA1CA2CA9PKLR | |
| Indigotindisulfonate SCHEMBL3206773 | 0.77 | CA12 (0.44) | CA12CA1CA2CA9PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208186-B2 | Latex comprising colorant and methods of making the same | XEROX CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170073499-A1 | LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2017-03-16 | — | — | US | disclosed |
| US-9580578-B2 | Latex comprising colorant and methods of making the same | XEROX CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160024276-A1 | LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2016-01-28 | — | — | US | disclosed |
| US-9213248-B2 | Latex comprising colorant and methods of making the same | XEROX CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-9090758-B2 | Phase change ink comprising modified naturally-derived colorants | XEROX CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150030977-A1 | LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140152748-A1 | Phase Change Ink Comprising Modified Naturally-Derived Colorants | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155625-A1 | Modified Naturally-Derived Colorants For Phase Change Ink Applications | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2061524-A2 | COLOR CHANGING SKIN SEALANT | Kimberly-Clark Worldwide, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032231-A2 | COLOR CHANGING SKIN SEALANT | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080063615-A1 | Color changing skin sealant | KIMBERLY-CLARK WORLDWIDE, INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155625-A1 | Modified Naturally-Derived Colorants For Phase Change Ink Applications | RB1, KAT2A, KAT5 | CA12 755/4885CA1 2605/4885CA2 1626/4885 |
| US-20080063615-A1 | Color changing skin sealant | CUTA, PROC, RBP1 | CA12 3202/4885CA1 4378/4885CA2 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.